Navigation Links
Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market
Date:7/31/2014

LONDON, July 31, 2014 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE: SNN), the global medical technology business, today announced its entry into the forefoot market with the launch of the HAT-TRICK™ Lesser Toe Repair System. Comprised of three separate repair options, the HAT-TRICK System includes products for metatarsophalangeal (MTP) ligament repair and reconstruction, a metatarsal osteotomy guide, and a revisable, all-PEEK implant for proximal Inter-phalanges (PIP) fusion, also known as hammer toe correction.

With the new HAT-TRICK System, surgeons have access to:

  • The HAT-TRICK MTP Joint Repair System, which provides a complete repair of the lesser MTP joint that is less invasive and more anatomic than current standard of care techniques,i
  • The HAT-TRICK Osteotomy Guide, which allows for a controlled, precise and reproducible approach that maintains the biomechanical axis of the metatarsal,ii and
  • The HAT-TRICK PIP Fusion System, which is an all-inside fusion of the PIP joint that is less invasive than other standard of care options.iii

"We are excited to expand our successful foot and ankle portfolio into the forefoot," says Mark Waugh, Vice President, Extremities and Limb Restoration for Smith & Nephew. "In addition to being a high-growth area, we believe there are tremendous opportunities for us to enhance the surgeon experience, simplify the procedures and, most importantly, improve patient outcomes."

Current market analysis shows that procedures such as lesser toe correction surgery are experiencing double-digit growth in the US.iv However, patient satisfaction research suggests that as many as 46% of hammer toe patients are unsatisfied with the outcome of their surgery using existing methods and technologies.v

"Although treating lesser toe deformities is extremely common, getting consistently predictable outcomes has eluded surgeons worldwide," explains orthopaedic surgeon Charles Saltzman, MD, chairman of the system's scientific advisory board. "Current standards of treatment are known to have unacceptably high complication rates."

The HAT-TRICK system is a new three-part approach designed to not only treat the deformity, but also the underlying problem that led to the deformity in the first place."

Editor's notes: The metatarsophalangeal joint connects the metatarsal bones of the foot and the proximal bones (proximal phalanges) of the toes – similar to the area of the hand called the knuckles.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

™Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

i Saltzman C. "The Development of a Novel Repair Technique for Metatarsophalengeal Instability Utilizing Cadaver Validated Computer Modeling: A Comparison with Current Techniques" International Foot & Ankle Conference. 2012 Sydney, Australia.

ii Internal testing, data on file.

iii Angirasa AK, Barrett MJ, Silvester D. Smart Toe® Implant Compared with Kirschner Wire Fixation for Hammer Digit Corrective Surgery: A Review of 28 Patients. J Foot Ankle Surg 2012; 51:711-713.

iv iData Research. "US Market For Small Bone & Joint Orthopedic Devices." 2013.

v Barg A, Courville XF, Nickisch F, Bachus KN, Saltzman C. Role of Collateral Ligaments in Metatarsophalangeal Stability: A Cadaver Study. Foot Ankle Int 2012; 33:877-882.


'/>"/>
SOURCE Smith & Nephew
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Smithsonian Explores Beginnings of Biotechnology
2. New Drug Applications, FDA Approvals, Approved Acquisitions, Divestitures and Licensing Agreements - Research Report on Merck, Allergan, Mylan, AstraZeneca, and GlaxoSmithKline
3. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
4. Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium
5. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma
6. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
7. Jennifer C. Smith, DVM DACLAM, Formerly of Taconic Farms, Inc. Joins the Veterinary Bioscience Institute as the Vice President of Research and Development
8. Executives from Johnson & Johnson, GlaxoSmithKline and California State Board of Pharmacy discuss pharmaceutical packaging challenges at Pharmapack North America 2013
9. Smith & Nephew releases new Modular Rail System in collaboration with Dr. Dror Paley
10. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
11. Smith & Nephew hosts thought-leading surgeons, showcases new technology at American Academy of Orthopaedic Surgeons annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):